InDex Pharmaceuticals Holding AB (publ) Profit Margin

InDex Pharmaceuticals Holding AB (publ) (INDEX.ST) currently reports a profit margin of -52.13% as of March 2024. That compares with 182.68% in the prior-year period — down 128.5% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore InDex Pharmaceuticals Holding AB (publ)'s profit margin history and peer comparisons.

InDex Pharmaceuticals Holding AB (publ)'s profit margin decreased from 182.68% to -52.13% — a 128.5% year-over-year decrease (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

InDex Pharmaceuticals Holding AB (publ)'s profit margin of -52.13% is lower than the Healthcare sector average of 9.48%. That is roughly 649.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but InDex Pharmaceuticals Holding AB (publ)'s current -52.13% should be judged against Healthcare norms (sector average: 9.48%) and against INDEX.ST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -52.13%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for InDex Pharmaceuticals Holding AB (publ), and consider following INDEX.ST for alerts when major investors trade the stock.